Live tape
Top 8, mentions 7d14,356NVDA4,865 mentions▲ +0.04GOOGL2,063 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,108 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

FULC

NASDAQ

Fulcrum Therapeutics (FULC)

3.66 USD +4.42% vs prior close
Fulcrum Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
279.2M USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−1.18 USD
Avg volume
691.4K

as of Jul 17, 2026

Have Fulcrum Therapeutics (FULC) insiders bought or sold shares recently?

FULC's newest Form 4 filing is dated 17 July 2026: none in the last 90 days.

Form 4

Have Fulcrum Therapeutics (FULC) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Jul 2026TANG KEVIN10% OwnerBuy50,945179K USD
16 Jul 2026TANG KEVIN10% OwnerBuy116,671415K USD
15 Jul 2026TANG KEVIN10% OwnerBuy107,377382K USD
14 Jul 2026TANG KEVIN10% OwnerBuy129,603463K USD
13 Jul 2026TANG KEVIN10% OwnerBuy12,96646K USD
26 Jun 2026Ezekowitz AlanDirectorSell18,00066K USD
02 Feb 2026Gould Robert JDirectorSell15,000161K USD
02 Jan 2026Gould Robert JDirectorSell15,000163K USD
15 Dec 2025Oltmans Curtis GaleChief Legal OfficerSell3,45245K USD
08 Dec 2025RA CAPITAL MANAGEMENT, L.P.Sell4,175,13958.4M USD
19 Nov 2025Gould Robert JSell15,000165K USD
Bought5 open-market purchases417,562$1.49M
Sold6 open-market sales4,241,591$58.98M

Which funds hold Fulcrum Therapeutics (FULC)?

9 of the 45 institutional funds we track reported a Fulcrum Therapeutics position for the quarter ended 30 Jun 2026 — a combined 49.4M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Fulcrum Therapeutics (FULC)?
FundPositionSharesValueShares q/q
D. E. Shaw & Co.Added3,044,38511.1M USD+87.5%
Citadel AdvisorsAdded2,704,5059.9M USD+109.2%
Renaissance TechnologiesAdded1,647,8006.0M USD+12,016.2%
Millennium ManagementAdded1,485,8035.4M USD+316.8%
Marshall WaceNew position1,358,4235.0M USD
AQR Capital ManagementAdded1,103,2614.0M USD+103.1%
Two Sigma InvestmentsAdded812,7663.0M USD+484.7%
Balyasny Asset ManagementTrimmed692,3722.5M USD−61.1%
Point72 Asset ManagementTrimmed651,4272.4M USD−68.6%
Man GroupExited

What has been filed or recorded for Fulcrum Therapeutics (FULC)?

The filings we hold for Fulcrum Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Fulcrum Therapeutics (FULC)?
And
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.34 USD
30 Jun 2026FinancialsTotal assets324.0M USDat period end
30 Jun 2026FinancialsTotal equity310.7M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.25 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.18 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−74.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.18 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.31 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.28 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.28 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −0.16 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.35 USD

What do people ask about Fulcrum Therapeutics (FULC)?

From live data
What is Fulcrum Therapeutics’ market cap?279.2M

Fulcrum Therapeutics is worth 279.2M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Fulcrum Therapeutics’ revenue?0

Fulcrum Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Fulcrum Therapeutics insiders bought or sold shares recently?

No Fulcrum Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 17 Jul 2026 (SEC Form 4). See Insiders

Which funds own Fulcrum Therapeutics?9 of 45

9 of the 45 funds we track reported a Fulcrum Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were D. E. Shaw & Co., Citadel Advisors and Renaissance Technologies. See Funds

When did Fulcrum Therapeutics last report earnings?−0.34

Fulcrum Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.34 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings